Research programme: selective androgen receptor modulators - Oncternal Therapeutics
Alternative Names: Andromustine; GTx 026; GTx-027; Libidarine; ProstarineLatest Information Update: 16 Apr 2020
At a glance
- Originator GTx; Merck & Co
- Developer Oncternal Therapeutics, Inc.
- Class Azasteroids; Benzamides; Small molecules
- Mechanism of Action Selective androgen receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Discontinued Breast cancer; Duchenne muscular dystrophy; Sarcopenia
Most Recent Events
- 31 Mar 2020 Oncternal Therapeutics terminates a license agreement with the University of Tennessee Research Foundation
- 07 Jun 2019 GTx has merged with Oncternal Therapeutics to form Oncternal Therapeutics
- 06 Jun 2019 Research programme: selective androgen receptor modulators - GTx is available for licensing as of 31 Dec 2018. https://www.gtxinc.com/